Silexion Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update

Silexion Therapeutics Corp (SLXN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Silexion Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update First patient dosed in the Phase 2/3 clinical trial of SIL204 in locally advanced pancreatic cancer at Tel Aviv Sourasky Medical Center, moving SIL204 into active patient

Event · Earnings
Original reporting
Published Nov 16, 2026, 11:01 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 16, 2026, 11:24 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$SLXN
Bullish
medium confidence
Mentioned
$SLXN
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$SLXNBullishMed
01

Why it matters

The filing provides the first public confirmation of trial initiation and recent financing, offering new data for investors.

02

Market read

First‑in‑human dosing is a material catalyst for a micro‑cap biotech; investors will reassess valuation based on trial progress and cash position.

03

What to watch

Potential regulatory delays and competition from other KRAS inhibitors.

Relevance 7/10Novelty 8/10Timing: today (SEC 8‑K filing)
AlphAI · Earnings readSLXN · Q3 2026 · ended 2026-09-30

Silexion reports Q3 2026 results: first SIL204 patient dosed in Phase 2/3 pancreatic cancer trial; cash $4,760 thousand and equity $2,968 thousand at September 30, 2026

↓Weak quarter

The company reports no revenue, a net loss of $2,533 thousand for the quarter and $8,817 thousand for nine months, and cash of $4,760 thousand. The filing references substantial doubt about going concern (Note 1(e)) and Nasdaq shareholders' equity and minimum bid price compliance matters. Operating activity advanced with the first patient dosed, but the balance sheet remains thin.

EPS · GAAP
$13.70

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
Research and development expenses, three months ended September 30, 2026GAAP$1.29M–decrease of 40.9%
Total operating expenses, three months ended September 30, 2026GAAP$2.68M––
Operating loss, three months ended September 30, 2026GAAP$2.68M––
Financial expenses (income), net, three months ended September 30, 2026GAAP−$151K––
Loss before income tax, three months ended September 30, 2026GAAP$2.53M––
Net loss, three months ended September 30, 2026GAAP$2.53M–decrease of 24.2%
Loss per share, basic and diluted, three months ended September 30, 2026GAAP$13.70––
Research and development expenses, nine months ended September 30, 2026GAAP$4.87M–increase of 28.9%
Total operating expenses, nine months ended September 30, 2026GAAP$9.11M––
Operating loss, nine months ended September 30, 2026GAAP$9.11M––
Financial expenses (income), net, nine months ended September 30, 2026GAAP−$296K––
Loss before income tax, nine months ended September 30, 2026GAAP$8.82M––
Income tax, nine months ended September 30, 2026GAAP* (less than $1 thousand)––
Net loss, nine months ended September 30, 2026GAAP$8.82M–increase of 17.3%
Loss per share, basic and diluted, nine months ended September 30, 2026GAAP$115.56––
Cash and cash equivalents, as of September 30, 2026GAAP$4.76M––
Total shareholders' equity, as of September 30, 2026GAAP$2.97M––
Total assets, as of September 30, 2026GAAP$6.83M––

Capital returns

  • No dividends or share repurchases are reported. The company completed a registered public offering in August 2026 with gross proceeds of approximately $2.5 million.
  • A warrant inducement transaction in September 2026 generated gross proceeds of approximately $0.84 million.
  • Sales of ordinary shares under the at-the-market facility in the third quarter generated gross proceeds of approximately $1.9 million.
  • A 1-for-10 reverse share split was effected on May 28, 2026, and a 1-for-24 reverse share split was effected on November 10, 2026, which is after quarter end. All share and per share amounts reflect these splits retroactively.
  • Ordinary shares issued and outstanding were 603,055 as of September 30, 2026, compared with 13,028 as of December 31, 2025, after split adjustment.

What drove it

  • Company explanation: the nine-month increase in R&D expenses related to the operational ramp-up for the Phase 2/3 clinical trial of SIL204.
  • Company explanation: the nine-month increase in net loss was mainly due to higher R&D expenses related to the Phase 2/3 clinical trial of SIL204.
  • Clinical activity: the Phase 2/3 trial of SIL204 in locally advanced pancreatic cancer started on July 29, 2026, at Tel Aviv Sourasky Medical Center, with the first patient dosed on September 30, 2026.
  • Trial design per the filing: a safety run-in cohort of approximately 18 patients, followed by a randomized cohort of approximately 166 patients.
  • Financing: a registered public offering (August 2026, approximately $2.5 million gross), a warrant inducement (September 2026, approximately $0.84 million gross) and at-the-market sales (approximately $1.9 million gross) during the third quarter.

Concerns

  • The filing references substantial doubt about the Company's ability to continue as a going concern, described in Note 1(e) to the unaudited condensed consolidated financial statements.
  • Cash and cash equivalents of $4,760 thousand compare with a nine-month operating loss of $9,113 thousand, and the company's cash balance declined from $5,991 thousand at December 31, 2025.
  • Shareholders' equity of $2,968 thousand is cited in the forward-looking statements among the Nasdaq continued listing matters, which include the shareholders' equity and minimum bid price requirements and the determination of the Nasdaq hearings panel.
  • The filing states that the Company may need to raise additional capital, including through its at-the-market facility, public and private offerings, warrant exercises and warrant inducement transactions.
  • The company reports no revenue in the filing, and the financial statements show only operating expenses and financial items.
  • G&A expenses rose 27.3% in the quarter and 20.0% over nine months. The filing does not explain the G&A increase.

What to watch

  • Enrollment progress in the safety run-in cohort (approximately 18 patients) and the randomized cohort (approximately 166 patients) of the Phase 2/3 trial.
  • Activation of additional Israeli oncology centers and German academic medical institutions, which the filing expects to join in the coming months.
  • Resolution of the going concern disclosure in Note 1(e) and the Company's ability to fund operations through its financing sources.
  • Status of the Nasdaq hearings panel process, shareholders' equity compliance and minimum bid price compliance following the November 10, 2026 1-for-24 reverse split.
  • Pharmacokinetic, cellular uptake kinetics and biodistribution studies, which the filing describes as ongoing.
  • Cash balance and equity trajectory from the $4,760 thousand and $2,968 thousand levels reported at September 30, 2026.

Balance sheet and cash flow

  • Cash and cash equivalents were $4,760 thousand as of September 30, 2026, compared with $5,991 thousand as of December 31, 2025, and $2.2 million as of June 30, 2026 (the latter from the Balance Sheet Highlights prose).
  • Restricted cash was $28 thousand (current) and $61 thousand (non-current) as of September 30, 2026.
  • Total assets were $6,827 thousand as of September 30, 2026, compared with $7,215 thousand as of December 31, 2025.
  • Total liabilities were $3,859 thousand as of September 30, 2026, compared with $4,612 thousand as of December 31, 2025.
  • Total current liabilities were $3,681 thousand as of September 30, 2026, compared with $2,758 thousand as of December 31, 2025.
  • Related Party Promissory Note was nil as of September 30, 2026, compared with $1,568 thousand as of December 31, 2025.
  • Total shareholders' equity was $2,968 thousand as of September 30, 2026, compared with $2,603 thousand as of December 31, 2025. The filing describes it as approximately $3.0 million at September 30, 2026.
  • Accumulated deficit was $63,983 thousand as of September 30, 2026, compared with $55,166 thousand as of December 31, 2025.
  • Additional paid-in capital was $64,997 thousand as of September 30, 2026, compared with $57,727 thousand as of December 31, 2025.
  • The filing does not present a cash flow statement or operating cash flow figure for the period.

Analysis

Silexion's third-quarter 2026 release is a clinical-stage update with no reported revenue. The operating loss was $2,684 thousand for the three months ended September 30, 2026, against $3,292 thousand a year earlier. Within that, R&D expenses fell to $1,286 thousand from $2,157 thousand, a decrease of 40.9%, while G&A expenses rose to $1,398 thousand from $1,135 thousand, an increase of 27.3%. The net loss for the quarter was $2,533 thousand, a decrease of 24.2% from $3,262 thousand. The filing does not explain the quarterly R&D decline or the G&A increase.

Over nine months the picture reverses. R&D expenses were $4,868 thousand against $3,765 thousand (an increase of 28.9%), and G&A expenses were $4,245 thousand against $3,461 thousand (an increase of 20.0%). The net loss for the nine months was $8,817 thousand against $7,500 thousand, an increase of 17.3%. The company attributes the R&D increase to the operational ramp-up of the Phase 2/3 trial of SIL204, and the higher net loss mainly to that R&D spending. Loss per share, basic and diluted, was $13.70 for the quarter and $115.56 for the nine months, both split-adjusted after the May 28, 2026 and November 10, 2026 reverse splits.

Operationally, the Phase 2/3 trial of SIL204 in locally advanced pancreatic cancer began on July 29, 2026, with the first patient dosed at Tel Aviv Sourasky Medical Center on September 30, 2026. The trial design calls for an initial safety run-in cohort of approximately 18 patients and a randomized cohort of approximately 166 patients. Additional Israeli and German sites are described as progressing through activation. The company also cites translational findings on immune pathways and KRAS mutations, which are preclinical and remain under study.

The balance sheet is the central constraint. Cash and cash equivalents were $4,760 thousand at September 30, 2026, against $5,991 thousand at December 31, 2025 and $2.2 million at June 30, 2026. Shareholders' equity was $2,968 thousand, up from $2,603 thousand at December 31, 2025, and total assets were $6,827 thousand. Third-quarter financings included a registered public offering of approximately $2.5 million gross, a warrant inducement of approximately $0.84 million gross and at-the-market sales of approximately $1.9 million gross. Nine-month operating expenses of $9,113 thousand exceed the period-end cash balance. The filing cites substantial doubt about the going concern assumption, and it lists Nasdaq shareholders' equity and minimum bid price matters among its forward-looking risk factors.

No guidance is provided, and no prior outlook was supplied for comparison. Readers should weigh the clinical milestone of the first dosed patient against the financing dependence the filing discloses. The figures that deserve the closest attention are the cash balance, the going concern note, and the Nasdaq compliance status.

Management, verbatim

In the third quarter, we began treating patients with SIL204 in our Phase 2/3 trial in pancreatic cancer. After opening our first clinical site at Tel Aviv Sourasky Medical Center in July, we dosed the first patient at the end of September.

Ilan Hadar, Chairman and Chief Executive Officer

This financial progress strengthens our balance sheet and supports the continued advancement of SIL204 as we enroll patients in the Phase 2/3 trial.

Mirit Horenshtein Hadar, Chief Financial Officer

Not in the filing

stated, not guessed
  • Revenue: the filing contains no revenue line, so revenue and its prior-period comparison are not reported.
  • Gross margin and cost of sales: not reported in the filing.
  • Prior-year change for total operating expenses and operating loss (three months and nine months): percentage changes are not printed.
  • Prior-year change for loss before income tax and financial expenses (income), net: percentage changes are not printed.
  • Prior-year change for loss per share (three months and nine months): not printed.
  • Prior-quarter (June 30, 2026) figures for R&D, G&A, operating loss and net loss: not printed in the release.
  • Prior-year comparison for cash and cash equivalents and shareholders' equity at September 30, 2026: the release compares to December 31, 2025, not to September 30, 2025.
  • Cash flow statement, operating cash flow, investing cash flow, financing cash flow and free cash flow: not presented in the release.
  • Guidance (revenue, gross margin, operating expenses, tax rate): not provided.
  • Prior-quarter June 30, 2026 cash figure of $2.2 million is printed in prose only and not in the balance sheet table.
  • Share price reaction, analyst consensus and price targets: not in the documents.

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. Guided figures in the outlook comparison come from the company’s previous release. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

Background

Silexion Therapeutics (NASDAQ: SLXN) filed an 8‑K reporting Q3 2026 results, a reverse split, and the first patient dosing in its SIL204 Phase 2/3 pancreatic cancer trial.

Company-level read

Ticker impact

$SLXNBullishMedium confidence
Context

First patient dosed in Phase 2/3 trial of SIL204 and Q3 financing disclosed in SEC 8‑K filing.

Expected impact

potential modest upside as market prices in the start of the Phase 2/3 trial and improved balance sheet.

Evidence & confidence

Biotech investors react to first-in-human dosing; cash remains limited so upside is constrained.

Market effects

May boost interest in KRAS‑targeted RNAi therapeutics and related biotech peers.

Limited to US biotech sector; no broader regional effect.

Low global impact beyond niche oncology investors.

Counterpoint

Trial start does not guarantee efficacy; cash burn could pressure the stock if results are delayed.

Key entities

  • Silexion Therapeutics

    Clinical‑stage biotech developing RNAi therapies for KRAS‑driven cancers.

Every SLXN earnings report

This story covers one filing. The ticker page keeps them all: each quarter's reported metrics with year-over-year and sequential comparisons, segments, guidance, and how the numbers landed against the company's own prior outlook.

Related articles

$SLXNMedAI 8/10

Silexion Therapeutics Announces First Patient Successfully Dosed in Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer

Silexion Therapeutics Corp (SLXN) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 Silexion Therapeutics Announces First Patient Successfully Dosed in Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer Global Phase 2/3 trial evaluates SIL204 in combination with standard chemotherapy in patients with locally advanced pancreatic

$SLXNMedAI 8/10

Silexion Therapeutics Announces First Patient Successfully Dosed in Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer

Silexion Therapeutics (SLXN) dosed the first patient in its Phase 2/3 trial of SIL204 for locally advanced pancreatic cancer. The trial combines SIL204 with standard chemotherapy. The study is being conducted at Tel Aviv Sourasky Medical Center and will expand to other sites in Israel and Germany. SIL204 is administered via a dual-route delivery strategy. The company aims to evaluate the potential of SIL204 to improve patient outcomes.

$SLXNMedAI 8/10

Silexion Therapeutics (SLXN) Stock Soars 61% After Hours: Here's What's Going On - Silexion Therapeutics

Silexion Therapeutics (SLXN) shares surged 61% after reporting positive preclinical results for SIL204, its lead cancer therapy. The study showed dose-dependent gene silencing in KRAS-driven cancer cells. The company is advancing clinical trials. SLXN has a $1.43M market cap, down 99.27% over the past year. Shares fell 4.57% to $0.25 during regular trading.